Anti‐Inflammatory Resveratrol Protects Mice From Early Mortality After Haematopoietic Stem Cell Transplantation
Journal of Cellular and Molecular Medicine · 2025
DOI: 10.1111/jcmm.70395 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Xiao Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong, China. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Resveratrol, Anti-Inflammatory Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Science, Technology and Innovation Commission of Shenzhen Municipality.
Abstract (Originalsprache)
The occurrence of inflammation subsequent to haematopoietic stem cell transplantation is associated with an elevated risk of transplant‐related mortality (TRM). However, the duration of inflammation and the potential efficacy of anti‐inflammatory agents in reducing TRM remain uncertain. We performed a comprehensive investigation to examine the post‐transplantation alterations of inflammatory mediators and to ascertain the correlation between inflammation level and TRM through the neutrophil–lymphocyte ratio, ELISAs and cytometric bead array. The findings revealed that the 30‐day interval following transplantation is characterised by the most pronounced inflammatory response in both human and murine subjects, thereby elevating the risk of TRM. The inflammation is primarily caused by myeloid bias during haematopoietic reconstitution, which is a commonly overlooked aspect in clinical transplantation, additionally, a lesser extent of irradiation‐induced injury. The administration of the anti‐inflammatory agent resveratrol has the potential to reduce systemic inflammation and TRM by suppressing the NOD‐like receptor signalling pathway and slowing down granulocyte implantation in HSCT mice. This approach did not impair the differentiation potential of haematopoietic stem cells. These findings demonstrate that the 30‐day post‐transplant period represents an opportunity to facilitate HSCT colonisation, mitigate transplant‐related adverse effects, and potentially reap the benefits of anti‐inflammatory treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong, China.
- Joint Laboratory of Guangdong-Hong Kong Universities for Vascular Homeostasis and Diseases, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong, China.
- Department of Anesthesiology, the First Affiliated Hospital, Jinan University, Guangzhou, Guangdong, China.
- School of Clinical Medicine, Weifang Medical University, Weifang, Shandong, China.
ORCID-Profile: Xiao Zhang
Förderung
- National Natural Science Foundation of China
- Science, Technology and Innovation Commission of Shenzhen Municipality
Zitieren
APA
Zhang, X., Yu, W., Sun, Y., Ye, X., He, Y., Huang, X., Wang, F., Lu, Y., & Zhang, J. (2025). Anti‐Inflammatory Resveratrol Protects Mice From Early Mortality After Haematopoietic Stem Cell Transplantation. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70395
Vancouver
Zhang X, Yu W, Sun Y, Ye X, He Y, Huang X, et al. Anti‐Inflammatory Resveratrol Protects Mice From Early Mortality After Haematopoietic Stem Cell Transplantation. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70395
BibTeX
@article{Zhang2025,
author = {Zhang, Xiao and Yu, Wei and Sun, Yimeng and Ye, Xinyu and He, Yu and Huang, Xin and Wang, Fuhao and Lu, Yi and Zhang, Jian},
title = {Anti‐Inflammatory Resveratrol Protects Mice From Early Mortality After Haematopoietic Stem Cell Transplantation},
journal = {Journal of Cellular and Molecular Medicine},
year = {2025},
doi = {10.1111/jcmm.70395}
}
EUVIMED